Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 19:387:e079183.
doi: 10.1136/bmj-2024-079183.

Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation

Elie A Akl  1   2 , Joanne Khabsa  3 , Claire Iannizzi  4 , Vanessa Piechotta  5 , Lara A Kahale  6 , James M Barker  7 , Joanne E McKenzie  8 , Matthew J Page  8 , Nicole Skoetz  4 ; PRISMA-LSR Group
Collaborators, Affiliations

Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation

Elie A Akl et al. BMJ. .

Abstract

Publications of living systematic reviews (LSRs) are increasing rapidly. Guidance facilitating transparent, complete, and accurate reporting of LSRs is needed. This paper reports the development of an extension of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement for LSRs (PRISMA-LSR). The PRISMA-LSR extension includes the PRISMA-LSR checklist, the PRISMA-LSR flow diagram, reporting recommendations for the LSR status, and an explanation and elaboration document. This extension has been developed as an “add-on” to the PRISMA 2020 statement, meaning it should be used in addition to the PRISMA 2020 statement. The PRISMA-LSR extension is expected to benefit authors, editors, peer reviewers, and users of LSRs through transparent, complete, and accurate reporting of LSRs.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. NS has received consulting fees as senior editor at Cochrane Cancer (2021). JEM and MJP act as PRISMA executive co-chairs (2023 to current) and do not receive any payment for this role; they have also co-led the development of the PRISMA 2020 statement, but have no financial conflict of interest in relation to use of the guideline. Tamara Kredo is a Cochrane Board member. Views expressed are her own. Patient and public involvement: Although the authors attempted to recruit consumers to be part of this study, they were not successful in recruiting anyone.

References

    1. Bendersky J, Auladell-Rispau A, Urrútia G, Rojas-Reyes MX. Methods for developing and reporting living evidence synthesis. J Clin Epidemiol 2022;152:89-100. 10.1016/j.jclinepi.2022.09.020 - DOI - PubMed
    1. Breuer C, Meerpohl JJ, Siemens W. From standard systematic reviews to living systematic reviews. Z Evid Fortbild Qual Gesundhwes 2023;176:76-81. 10.1016/j.zefq.2022.11.007 - DOI - PubMed
    1. Elliott JH, Turner T, Clavisi O, et al. . Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap. PLoS Med 2014;11:e1001603. 10.1371/journal.pmed.1001603 - DOI - PMC - PubMed
    1. Zheng Q, Xu J, Gao Y, et al. . Past, present and future of living systematic review: a bibliometrics analysis. BMJ Glob Health 2022;7:e009378. 10.1136/bmjgh-2022-009378 - DOI - PMC - PubMed
    1. Elliott JH, Synnot A, Turner T, et al. Living Systematic Review Network . Living systematic review: 1. Introduction-the why, what, when, and how. J Clin Epidemiol 2017;91:23-30. 10.1016/j.jclinepi.2017.08.010 - DOI - PubMed

LinkOut - more resources